Osimertinib Not Yet Recruiting Phase 2 Trials for Metastatic Non Small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03497767A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases